文献速递急性肾损伤遗传性与小管间质肾病

英夫利西单抗治疗III或IV级免疫检查点抑制剂相关肾炎的临床与转化证据

Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence.
PubMed 文献 · Kidney Int Rep · 2025-10-30

联合治疗组在开始激素30天内使用英夫利西单抗者肾脏应答时间显著改善,但无进展生存无差异;NanoString分析显示药物及ICI相关AIN中免疫表达升高,TNF-α表达与肾脏应答相关。

要点

  • 英夫利西单抗可能改善III或IV级ICI-AIN的肾脏应答时间
  • 联合治疗未显著延长肾脏应答持续时间或影响肿瘤无进展生存
  • TNF-α表达升高与肾脏应答相关,支持其作为治疗靶点

核心结论

  • 英夫利西单抗联合糖皮质激素可能较单用激素在III或IV级ICI-AIN中提供治疗优势。

研究设计与样本

  • 27例接受单用激素,28例接受激素联合英夫利西单抗;另对86例肾脏样本(48例ICI暴露)进行NanoString分析。

主要发现

  • 在开始激素30天内使用英夫利西单抗的患者肾脏应答时间较单用激素显著改善。
  • 英夫利西单抗组肾脏应答持续时间在单变量分析中较长,但多变量分析无显著差异,且无进展生存无差异。
  • NanoString分析显示药物及ICI相关AIN的免疫表达高于对照,TNF-α表达升高与肾脏应答相关。

临床怎么用

  • 对于III或IV级ICI-AIN,可考虑在糖皮质激素基础上早期(30天内)加用英夫利西单抗以改善肾脏应答。

局限性

  • 回顾性单中心设计,样本量有限,可能存在选择偏倚。
  • 英夫利西单抗对肾脏应答持续时间的获益在多变量分析中未达显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute interstitial nephritis (AIN) is a common presentation of immune checkpoint inhibitor (ICI) toxicity. Increased tumor necrosis factor (TNF)-α expression has been observed in ICI-induced AIN (ICI-AIN). In this study, we compared treatment with glucocorticoids plus infliximab to glucocorticoids only in stage III or IV ICI-AIN. We conducted retrospective NanoString analysis of ICI-exposed kidney samples to identify associated gene signatures and possible association with TNF-α expression. METHODS: We reviewed the records of patients who received ICI, developed acute kidney injury (AKI), and underwent kidney biopsy at MD Anderson Cancer Center from January 2022 to October 2024. Fifty-five patients had AIN and stage III or IV AKI. 27 received steroids only and 28 received steroids plus infliximab. Time to renal response (TTR), duration of renal response (DORR), and cancer progression-free survival (PFS) were estimated using the Kaplan-Meier method. The log-rank test assessed survival differences between groups. Cox proportional hazards analyses were conducted on TTR and DORR, with treatment as a time-dependent covariate for TTR. Using NanoString technology, inflammatory gene signatures were evaluated in 86 kidney samples, of which 48 were ICI-exposed. RESULTS: No baseline differences were observed between groups. TTR was significantly improved in patients exposed to infliximab within 30 days of starting steroids compared with steroid-only. DORR was longer in infliximab group in univariate but not multivariate analysis, and no PFS difference was observed. In NanoString analysis, immune expression was higher in drug- and ICI-AIN compared with controls. Elevated TNF-α expression in drug- and ICI-AIN correlated with renal response. CONCLUSION: Infliximab use may offer a therapeutic advantage over steroids alone in stage III or IV ICI-AIN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Youssef N, Habeeb M, Chen H, et al. Infliximab for Grade III or IV Immune Checkpoint Inhibitor Nephritis Clinical and Translational Evidence. Kidney Int Rep. 2025. PMID: 41541786. doi:10.1016/j.ekir.2025.10.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。